Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR240550 plus gemcitabine/carboplatin in metastatic triple-negative breast cancer
NL-OMON34839Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of iniparib in triple-negative breast cancer (TNBC) (2 arms), sponsored by Sanofi. Primary endpoint: Objective response rate. Started May 2010; status: active, not recruiting.
02
Drugs
iniparib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NL-OMON34839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34839.